• About us
• Contact

Advertisement

Organisation › Details

Galapagos N.V. (Euronext + Nasdaq: GLPG)

Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *

 

	Start	1999-06-01 established_pre
	Industry	genomics/genetics
	Street	Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3
	City	2800 Mechelen
	Tel	+32-15342900
		Address record changed: 2020-12-02
Basic data	Employees	F: 1,001 to 5,000 (2019-12-31)
	Currency	EUR
	Annual sales	895,890,000 (revenues + other income, total, consolidated (2019) 2019-12-31)
	Profit	149,845,000 (2019-12-31)
	Cash	5,780,832,000 (2019-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Galapagos (Group)

• [1] Galapagos N.V.. (10/15/20). "Press Release: Galapagos and Servier Report Topline Results for ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086 in Knee Osteoarthritis Patients". Mechelen & Paris....
• [2] Evotec SE. (5/14/19). "Press Release: Evotec SE Reports First Quarter 2019 Results and Provides Corporate Update". Hamburg....
• [3] Galapagos N.V.. (11/27/18). "Press Release: Galapagos Receives Fast Track Designation from FDA for GLPG1972/S201086 in Osteoarthritis". Mechelen....
• [4] Galapagos N.V.. (7/27/17). "Press Release: Servier Licenses GLPG1972 in Osteoarthritis from Galapagos". Mechelen & Suresnes....
• [5] Galapagos N.V.. (7/27/17). "Press Release: Solid Financials Support R&D Progress. First Half-year financial Results". Mechelen....
• [6] Pharnext S.A.. (3/9/17). "Press Release: Pharnext Announces R&D Agreement with Galapagos to Generate a New Pipeline of Synergistic Drug Combinations". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.